Located in regions of the brain responsible for Parkinson’s disease, Omeros is the first to link its novel target to the treatment of any movement disorder, including Parkinson’s disease and restless legs syndrome. Omeros will continue to retain all of its rights associated with this novel target.
Under Omeros’s collaboration with The Parkinson’s Institute, preclinical studies using a widely accepted and highly predictive model for the symptomatic treatment of Parkinson’s disease are being conducted on one or more compounds that block Omeros’s proprietary target.
Gregory Demopulos, chairman and CEO of Omeros, said: “We are pleased that the Michael Fox Foundation is joining our efforts to develop a novel treatment for Parkinson’s disease. The Foundation is a well-recognized leader in Parkinson’s research, and its support will be key to testing the potential of our proprietary approach for treating patients living with the disease.”